GlassScriptPhysician profile
Andrew Alpar
NPI 1750368510
$1,420.35
in general payments reported to CMS, 2019-2025
9 companies · $42.01 in 2025
The $42.01 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $65.75 · 2021: $231 · 2022: $307 · 2023: $281 · 2024: $50.65 · 2025: $42.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.19 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $300.56 | 2021-2025 | |
| Amgen INC. | $257.63 | 2019-2020 | |
| Vifor Pharma, INC. | $254.77 | 2019-2023 | Veltassa |
| Glaxosmithkline, LLC. | $243.34 | 2022-2024 | Benlysta, Jesduvroq |
| Astrazeneca Pharmaceuticals LP | $187.51 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $97.81 | 2019-2024 | Velphoro |
| Nxstage Medical, INC. | $29.29 | 2019 | |
| Akebia Therapeutics INC | $27.84 | 2019 | |
| Outset Medical INC | $21.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Alpar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.